DP-R213 Pharmacokinetics Study
Study Details
Study Description
Brief Summary
A randomized, open-label, crossover, Phase I clinical trial to compare the pharmacokinetics of DP-R213 (Raloxifenel and Cholecaliferol fixed dose combinations) in comparison to each component administered alone in healthy male volunteers.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 1 |
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: RT group combination dose of Raloxifene and Cholecaliferol and DP-R213 in order |
Drug: DP-R213
Investigational product is prescribed to all of randomized subjects
Drug: Raloxifene
Investigational product is prescribed to all of randomized subjects
Drug: Cholecaliferol
Investigational product is prescribed to all of randomized subjects
|
Experimental: TR group combination dose of Raloxifene and Cholecaliferol and DP-R213 in order |
Drug: DP-R213
Investigational product is prescribed to all of randomized subjects
Drug: Raloxifene
Investigational product is prescribed to all of randomized subjects
Drug: Cholecaliferol
Investigational product is prescribed to all of randomized subjects
|
Outcome Measures
Primary Outcome Measures
- Area under the plasma concentration versus time curve (AUC) [up to 96 hours post dose]
- Peak Plasma Concentration (Cmax) [up to 96 hours post dose]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
IBW ±20%
-
signed the informed consent form prior to the study participation
Exclusion Criteria:
-
Clinically significant disease
-
Previously donate whole blood within 2 months or component blood within 1 month
-
Clinically significant allergic disease
-
Taken IP in other trial within 3 months
-
An impossible one who participates in clinical trial by investigator's decision including laboratory test result
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Alvogen Korea
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- DP-CTR213-I-01